Watson confirms Welchol patent challenge
PARSIPPANY, N.J. — Watson Pharmaceuticals is hoping to become the first company to market a generic treatment for cholesterol.
The drug maker said Wednesday that it had filed with the Food and Drug Administration for approval of a generic version of Welchol (colesevelam hydrochloride) tablets in the 625-mg strength, made by Daiichi Sankyo, thus challenging the patents covering the drug.
Daiichi Sankyo and Genzyme filed a patent infringement suit against Watson Monday in the U.S. District Court for the District of Delaware, alleging that Watson infringed on two patents covering Welchol. Under the provisions of the Hatch-Waxman Act, the suit puts a stay of FDA approval on the drug until September 2013, or until the companies resolve the matter before the court.
Welchol had sales of $336 million during the 12-month period ended in February 2010, according to IMS Health.
Amber, Kubat join NeHII
OMAHA, Neb. — Specialty pharmacy provider Amber Pharmacy and pharmacy retailer Kubat Pharmacy have joined the first network to electronically exchange clinical patient information and medication therapy with healthcare providers in and around Nebraska, the Nebraska Health Information Initiative said Wednesday.
NeHII — a nonprofit health information exchange designed to allow the sharing of clinical and administrative data between providers in Nebraska and surrounding states — said that as part of the exchange, the pharmacies would have secure access to customers’ most current and accurate medication history and information, allowing them to set new standards for safety and care.
“We are delighted to be the first pharmacy in the state of Nebraska to join the NeHII network,” Amber Pharmacy president Mike Agostino said. “Amber Pharmacy has been in the forefront of providing prescription services to the transplant community for almost 15 years.”
Salix granted three patents for Xifaxan
RALEIGH, N.C. — The U.S. Patent and Trademark Office has awarded Salix Pharmaceuticals three patents related to a drug used for travelers’ diarrhea.
Salix announced Wednesday that it had secured patents for the drug Xifaxan (rifaximin) covering its methods of treating travelers’ diarrhea, as well as two related to the drug’s chemical composition.
The patents are set to expire between 2024 and 2029.